| Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. | |
MedLine Citation:
|
PMID: 19046748 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Eicosanoids are lipid mediators that may play a role in atherosclerosis. We investigated the association of common genetic variation in prostaglandin H synthase 1 (PTGS1), prostaglandin H synthase 2 (PTGS2), thromboxane A2 synthase (TBXAS1), prostacyclin synthase (PTGIS), prostaglandin E synthase (PTGES), 5-lipoxygenase activating protein (ALOX5AP), 12-lipoxygenase (ALOX12) and 15-lipoxygenase (ALOX15) with the risks of myocardial infarction (MI) and ischemic stroke. A secondary aim was to replicate the interaction of PTGS2 rs20417 (-765G to C) with aspirin use on coronary heart disease risk observed in the Atherosclerosis Risk in Communities Study (ARIC). METHODS: We conducted a case-control study in a large Health Maintenance Organization. Cases were men and women, aged 30-79 years with incident non-fatal myocardial infarction (n=1063) or ischemic stroke (n=469) between January 1995 and December 2004. Controls (n=3462) were randomly selected and frequency matched to cases on age, sex, hypertension and calendar year. RESULTS: Common variation in TBXAS1 and PTGIS was associated with MI risk (p-value for global Chi-square test, 0.01 and 0.03, respectively). Common variation in ALOX5AP, ALOX12, ALOX15, PTGS1, PTGS2 and PTGES was not associated with risks of MI and ischemic stroke. We replicated the observation of the Atherosclerosis Risk in Communities Study and observed an interaction of rs20417 with aspirin use on myocardial infarction risk (p for interaction=0.03). CONCLUSIONS: Study results suggest that variation in TBXAS1 and PTGIS may influence MI risk, and carriers of rs20417C allele might derive greater benefits from aspirin use in primary prevention. |
Authors:
|
Rozenn N Lemaitre; Kenneth Rice; Kristin Marciante; Joshua C Bis; Thomas S Lumley; Kerri L Wiggins; Nicholas L Smith; Susan R Heckbert; Bruce M Psaty |
Related Documents
:
|
25045668 - Angiotensin converting enzyme inhibition reduces cardiovascular responses to acute stre... 3377578 - Predictors of length of hospitalization after cardiac surgery. 10551688 - Evidence against a role of physiological concentrations of estrogen in post-myocardial ... 20643648 - Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes ad... 17920368 - Usefulness of tissue doppler velocity and strain dyssynchrony for predicting left ventr... 16550308 - Influence of weight loss on myocardial performance index. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural Date: 2008-11-01 |
Journal Detail:
|
Title: Atherosclerosis Volume: 204 ISSN: 1879-1484 ISO Abbreviation: Atherosclerosis Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-25 Completed Date: 2009-08-10 Revised Date: 2014-09-18 |
Medline Journal Info:
|
Nlm Unique ID: 0242543 Medline TA: Atherosclerosis Country: Ireland |
Other Details:
|
Languages: eng Pagination: e58-63 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Arachidonate Lipoxygenases / genetics Aspirin / therapeutic use Brain Ischemia / enzymology, genetics*, prevention & control Case-Control Studies Cyclooxygenase 1 / genetics Cyclooxygenase 2 / genetics Cytochrome P-450 Enzyme System / genetics* Eicosanoids / metabolism* Female Gene Frequency Genetic Predisposition to Disease Humans Intramolecular Oxidoreductases / genetics Male Middle Aged Myocardial Infarction / enzymology, genetics*, prevention & control Odds Ratio Platelet Aggregation Inhibitors / therapeutic use Polymorphism, Single Nucleotide* Risk Assessment Risk Factors Stroke / enzymology, genetics*, prevention & control Thromboxane-A Synthase / genetics* |
| Grant Support | |
ID/Acronym/Agency:
|
AG09556/AG/NIA NIH HHS; HL43201/HL/NHLBI NIH HHS; HL60739/HL/NHLBI NIH HHS; HL68639/HL/NHLBI NIH HHS; HL68986/HL/NHLBI NIH HHS; HL73410/HL/NHLBI NIH HHS; HL74745/HL/NHLBI NIH HHS; R01 AG009556/AG/NIA NIH HHS; R01 AG009556-05/AG/NIA NIH HHS; R01 HL043201/HL/NHLBI NIH HHS; R01 HL043201-13/HL/NHLBI NIH HHS; R01 HL060739/HL/NHLBI NIH HHS; R01 HL060739-04/HL/NHLBI NIH HHS; R01 HL068639/HL/NHLBI NIH HHS; R01 HL068639-04/HL/NHLBI NIH HHS; R01 HL068986/HL/NHLBI NIH HHS; R01 HL068986-04/HL/NHLBI NIH HHS; R01 HL073410-04/HL/NHLBI NIH HHS; R01 HL074745/HL/NHLBI NIH HHS; R01 HL074745-04/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Eicosanoids; 0/Platelet Aggregation Inhibitors; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.13.11.-/Arachidonate Lipoxygenases; EC 1.14.99.1/Cyclooxygenase 1; EC 1.14.99.1/Cyclooxygenase 2; EC 1.14.99.1/PTGS1 protein, human; EC 1.14.99.1/PTGS2 protein, human; EC 5.3.-/Intramolecular Oxidoreductases; EC 5.3.99.3/prostaglandin-E synthase; EC 5.3.99.4/PTGIS protein, human; EC 5.3.99.5/Thromboxane-A Synthase; R16CO5Y76E/Aspirin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Improvements to cardiovascular gene ontology.
Next Document: In-capillary determination of creatinine with electrophoretically mediated microanalysis: characteri...